These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

463 related articles for article (PubMed ID: 24399081)

  • 21. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States.
    Baker KS; Loberiza FR; Yu H; Cairo MS; Bolwell BJ; Bujan-Boza WA; Camitta BM; Garcia JJ; Ho WG; Liesveld JL; Maharaj D; Marks DI; Schultz KR; Wiernik P; Zander AR; Horowitz MM; Keating A; Weisdorf DJ
    J Clin Oncol; 2005 Oct; 23(28):7032-42. PubMed ID: 16145067
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subsequent malignancies after allogeneic hematopoietic stem cell transplantation.
    Gündüz M; Özen M; Şahin U; Toprak SK; Civriz Bozdağ S; Kurt Yüksel M; Arslan Ö; Özcan M; Demirer T; Beksaç M; İlhan O; Gürman G; Topçuoğlu P
    Clin Transplant; 2017 Jul; 31(7):. PubMed ID: 28432802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-thymocyte-globulin as part of the preparative regimen prevents graft failure and severe graft versus host disease (GvHD) in allogeneic stem cell transplantation from unrelated donors.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Dürken M; Graf von Finkenstein F; Erttmann R; Kabisch H; Schafhausen P; Jaburg N; Löliger C; Zander AR
    Ann Hematol; 2001 Apr; 80(4):209-15. PubMed ID: 11401086
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of azathioprine for graft-vs-host disease is the major risk for development of secondary malignancies after haematopoietic stem cell transplantation: a nationwide population-based study.
    Chien SH; Liu CJ; Hong YC; Teng CJ; Hu YW; Shen CC; Ku FC; Chen SC; Yeh CM; Chiou TJ; Gau JP; Tzeng CH
    Br J Cancer; 2015 Jan; 112(1):177-84. PubMed ID: 25314066
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Increased risk of severe acute graft-versus-host disease in low body mass index patients undergoing haploidentical allogeneic stem cell transplantation].
    Chen Y; Xu L; Liu D; Liu K; Chen H; Zhang X; Wang F; Wang J; Wang Y; Han W; Chen Y; Yan C; Zhao T; Huang X
    Zhonghua Nei Ke Za Zhi; 2014 Sep; 53(9):710-4. PubMed ID: 25511404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk factors for acute kidney injury in patients undergoing allogeneic hematopoietic stem cell transplantation.
    Yu ZP; Ding JH; Chen BA; Liu BC; Liu H; Li YF; Ding BH; Qian J
    Chin J Cancer; 2010 Nov; 29(11):946-51. PubMed ID: 20979694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral malignancies following HSCT: graft versus host disease and other risk factors.
    Demarosi F; Lodi G; Carrassi A; Soligo D; Sardella A
    Oral Oncol; 2005 Oct; 41(9):865-77. PubMed ID: 16084755
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.
    Cao TM; Kusnierz-Glaz C; Valone F; Stockerl-Goldstein KE; Hu WW; Johnston L; Blume KG; Strober S; Negrin RS
    Cancer; 2001 Jun; 91(12):2205-13. PubMed ID: 11413507
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR).
    Gabriel M; Shaw BE; Brazauskas R; Chen M; Margolis DA; Sengelov H; Dahlberg A; Ahmed IA; Delgado D; Lazarus HM; Gibson B; Myers KC; Kamble RT; Abdel-Mageed A; Li CK; Flowers MED; Battiwalla M; Savani BN; Majhail N; Shaw PJ
    Biol Blood Marrow Transplant; 2017 Aug; 23(8):1320-1326. PubMed ID: 28411175
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood].
    Kusminsky G; Foncuberta MC; Aversa L; Drelichman G; Freigeiro D; Burgos R; Irrazabal C; Gonzalez G; Dictar M; Niborski R; Kohan A; Sanchez Avalos JC
    Medicina (B Aires); 2000; 60(2):179-87. PubMed ID: 10962806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Second cancers and late mortality in Australian children treated by allogeneic HSCT for haematological malignancy.
    Nelson AS; Ashton LJ; Vajdic CM; Le Marsney RE; Daniels B; Nivison-Smith I; Wilcox L; Dodds AJ; O'Brien TA;
    Leukemia; 2015 Feb; 29(2):441-7. PubMed ID: 24962016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Clinical study on haploid HLA-matched hematopoietic stem cell transplantation for treatment of malignant hematological disease].
    Sun AN; Wu DP; Wang Y; Qiu HY; Jin ZM; Miao M; Tang XW; Fu ZZ; Ma X; Han Y; He GS; Chen SN; Xue SL; Zhao Y
    Ai Zheng; 2006 Aug; 25(8):1019-22. PubMed ID: 16965686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transplantation of peripheral blood progenitor cells from HLA-identical sibling donors. European Group for Blood and Marrow Transplantation (EBMT).
    Schmitz N; Bacigalupo A; Labopin M; Majolino I; Laporte JP; Brinch L; Cook G; Deliliers GL; Lange A; Rozman C; Garcia-Conde J; Finke J; Domingo-Albos A; Gratwohl A
    Br J Haematol; 1996 Dec; 95(4):715-23. PubMed ID: 8982051
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New malignant diseases after allogeneic marrow transplantation for childhood acute leukemia.
    Socié G; Curtis RE; Deeg HJ; Sobocinski KA; Filipovich AH; Travis LB; Sullivan KM; Rowlings PA; Kingma DW; Banks PM; Travis WD; Witherspoon RP; Sanders J; Jaffe ES; Horowitz MM
    J Clin Oncol; 2000 Jan; 18(2):348-57. PubMed ID: 10637249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Donor Lymphocyte Infusions for Chronic Myeloid Leukemia Relapsing after Allogeneic Stem Cell Transplantation: May We Predict Graft-versus-Leukemia Without Graft-versus-Host Disease?
    Radujkovic A; Guglielmi C; Bergantini S; Iacobelli S; van Biezen A; Milojkovic D; Gratwohl A; Schattenberg AV; Verdonck LF; Niederwieser DW; de Witte T; Kröger N; Olavarria E;
    Biol Blood Marrow Transplant; 2015 Jul; 21(7):1230-6. PubMed ID: 25797175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Central nervous system relapse of leukemia after allogeneic hematopoietic stem cell transplantation.
    Oshima K; Kanda Y; Yamashita T; Takahashi S; Mori T; Nakaseko C; Fujimaki K; Yokota A; Fujisawa S; Matsushima T; Fujita H; Sakura T; Okamoto S; Maruta A; Sakamaki H;
    Biol Blood Marrow Transplant; 2008 Oct; 14(10):1100-1107. PubMed ID: 18804039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. "Risk of de novo or secondary cancer after solid organ or allogeneic haematopoietic stem cell transplantation".
    Wareham NE; Li Q; Sengeløv H; Da Cunha-Bang C; Gustafsson F; Heilmann C; Perch M; Rasmussen A; Sørensen SS; Mocroft A; Lundgren JD
    J Cancer Res Clin Oncol; 2019 Dec; 145(12):3125-3135. PubMed ID: 31587105
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex Vivo CD34
    Barba P; Hilden P; Devlin SM; Maloy M; Dierov D; Nieves J; Garrett MD; Sogani J; Cho C; Barker JN; Kernan NA; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Prockop S; Sauter C; Tamari R; van den Brink MR; Avecilla ST; Meagher R; O'Reilly RJ; Goldberg JD; Young JW; Giralt S; Perales MA; Ponce DM
    Biol Blood Marrow Transplant; 2017 Mar; 23(3):452-458. PubMed ID: 28017734
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Second solid cancers after allogeneic hematopoietic stem cell transplantation.
    Gallagher G; Forrest DL
    Cancer; 2007 Jan; 109(1):84-92. PubMed ID: 17131350
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Who is the best hematopoietic stem-cell donor for a male patient with acute leukemia?
    Ringdén O; Labopin M; Solders M; Beelen D; Arnold R; Ehninger G; Milpied N; Niederwieser D; Hamladji RM; Kyrcz-Krzemien S; Ganser A; Socié G; Stelljes M; Volin L; Craddock C; Mohty M;
    Transplantation; 2014 Sep; 98(5):569-77. PubMed ID: 24798307
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.